AXSOME THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 72.5 USD | -1.60% |
|
-3.07% | -8.91% |
Presenter SpeechAshwani Verma (Analysts)Great. Good day, everyone. Welcome to Bank of America ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
72.5
USD
Average target price
123.6
USD
Spread / Average Target
+70.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.91% | 3.44B | |
| -2.61% | 89.08B | |
| +3.55% | 40.9B | |
| -14.40% | 32.25B | |
| +55.89% | 25.14B | |
| -15.96% | 15.39B | |
| -15.50% | 11.91B | |
| -41.29% | 11.89B | |
| -11.75% | 11.64B | |
| +7.87% | 9.03B |
- Stock Market
- Equities
- AXSM Stock
- News Axsome Therapeutics, Inc.
- Transcript : Axsome Therapeutics, Inc. Presents at BofA Securities 2021 Virtual Health Care Conference, May-11-2021 04
